Evidence map›Paper›PMID 38294563›Full record

SynthesisSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2024

The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis.

Bangsheng Chen, Anyi Xu, Yujing He, Yueming Zhang, Dongying Cheng, Yingying Fang, Jiale Ruan, Min Dai, Yu Wang, Jie Zhang

Abstract readMeta-AnalysisReview
PubMed Publisher
In one paragraph

Synthesis in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bangsheng ChenEmergency Medical Center, Ningbo Yinzhou No. 2 Hospital, Ningbo, Zhejiang, China.
Anyi XuThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yujing HeThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yueming ZhangIntensive Care Unit, Hospital of Zhejiang People's Armed Police, Hangzhou, Zhejiang, China.
Dongying ChengCommunity Department, Ningbo Yinzhou No. 3 Hospital, Ningbo, Zhejiang, China.
Yingying FangThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Jiale RuanThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Min DaiThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yu WangThe First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Jie ZhangEmergency Department, Zhuji People's Hospital, No.9, Jianmin Road, Taozhu Street, Shaoxing, 311899, Zhejiang, China. immunolung28@163.com.
Zhejiang Chinese Medical University · CNNingbo No. 2 Hospital · CNShaoxing No.6 People's Hospital · CN

Funding

Ningbo Natural Science Foundation 2022J039The Medical and Health Research Project of Zhejiang 2022KY343The Science and Technology Project of Yinzhou 2022AS069
6 · The paper itself

Abstract

backgroundThis study aims to investigate the effect of PD-1/PD-L1 immunotherapy on cardiac-related adverse events in patients with advanced or metastatic lung cancer.

methodsWe conducted a detailed search in PubMed, Web of Science, Cochran, and Embase for articles on the application of immunotherapy for lung cancer and report cardiac-related adverse events with respect to myocardial ischemia, pericardial effusion, myocarditis, and electrophysiology. The dichotomous variables were assessed by relative risk (RR) and 95% confidence intervals (CI).

resultsA total of 7132 subjects were included in 12 phase III randomized controlled trials (RCTs). The results showed that under the fixed effects model, the probability of cardiac-related adverse events in pericardial effusion was higher in the experimental group than in the control group (RR 2.30, 95% CI 1.01-5.21, P = 0.05). Under the random effects model, there was no statistical difference between the two groups (RR 2.03, 95% CI 0.81-5.12, P = 0.13). No statistical difference is observed between the experimental group and the control group (under the fixed effects model and the random effects model) for other cardiac-related adverse events, including myocarditis, acute coronary syndrome, myocardial infarction, acute myocardial infarction, myocardial ischemia, unstable angina, ventricular tachycardia, supraventricular tachycardia, tachycardia, bradycardia, atrial flutter, atrial fibrillation, cardiac failure, cardiac arrest, cardiopulmonary failure, acute heart failure, cardiac arrest (all P > 0.05).

conclusionsPD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer is generally safe for cardiac-related adverse events.

Indexed as

Heart FailureLung NeoplasmsMyocardial IschemiaMyocarditisPericardial EffusionB7-H1 AntigenHumansImmunotherapyProgrammed Cell Death 1 ReceptorRandomized Controlled Trials as TopicB7-H1 AntigenProgrammed Cell Death 1 ReceptorCardiotoxicityImmunotherapyMeta-analysisPD-1/PD-L1Pericardial effusionSafety

Identifiers

PMID38294563
OpenAlexW4391390025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.